Pharmaceutical company Arrakis Inc has raised $ 75 m to develop targeted RNA therapies . The Nextech Invest and venBio Partners - led series of funding was also backed by new investors Discovery Funds , HBM Healthcare , GV , WuXi AppTec Venture and New Venture Investments , along with existing backers including Canaan Partners , Advent Life Sciences , Pfizer Ventures , Celgene , Osage University Partners and Henri Termeer . Arrakis said it would use the funding to bring at least one of its RNA therapies to clinical development and had a focus on oncology and other diseases . Photo: The company has $ 100 m of funding .
Pharmaceutical company Arrakis Inc has raised $ 75 m to develop targeted RNA therapies . The Nextech Invest and venBio Partners - led series of funding was also backed by new investors Discovery Funds , HBM Healthcare , GV , WuXi AppTec Venture and New Venture Investments , along with existing backers including Canaan Partners , Advent Life Sciences , Pfizer Ventures , Celgene , Osage University Partners and Henri Termeer . Arrakis said it would use the funding to bring at least one of its RNA therapies to clinical development and had a focus on oncology and other diseases . The company has $ 100 m of funding .